Who
Eric Aguiar
Director
Company insider
Files Form 4 as: Director, BridgeBio Pharma; Director, Biomea Fusion; Director, Invitae; Director and 10% owner, Eidos Therapeutics; Director, Biohaven Pharmaceutical Holding Co.
In numbers
- Trades disclosed
- 100
- Buys
- 3
- Sells
- 11
- Bought
- $55.1M
- Sold
- $5.5M
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 4 Nov 2015
- Last trade
- 22 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —3,990 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,277 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,277 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —3,990 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | BMEA Biomea Fusionoption or derivative · Biotechnology | SEC FORM 4 Code A | —196,299 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | BMEA Biomea Fusionoption or derivative · Biotechnology | SEC FORM 4 Code A | —196,299 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,425 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —6,589 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | BMEA Biomea Fusionoption or derivative · Biotechnology | SEC FORM 4 Code A | —91,970 at $0.00 | filing |
| 21 Jun 2024filed 25 Jun 2024 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,014 at $0.00 | filing |
| 12 Jun 2024filed 13 Jun 2024 | BMEA Biomea Fusionoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,025 at $0.00 | filing |
| 21 Jun 2023filed 23 Jun 2023 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,501 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | BMEA Biomea Fusionoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,989 at $0.00 | filing |
| 27 Apr 2023filed 1 May 2023 | Invitaeoption or derivative | SEC FORM 4 Code A | —28,901 at $0.00 | filing |
| 27 Apr 2023filed 1 May 2023 | Invitae | SEC FORM 4 Code A | —70,422 at $0.00 | filing |
| 22 Jun 2022filed 24 Jun 2022 | BMEA Biomea Fusionoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,867 at $0.00 | filing |
| 22 Jun 2022filed 24 Jun 2022 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —104,921 at $0.00 | filing |
| 28 Apr 2022filed 2 May 2022 | Invitaeoption or derivative | SEC FORM 4 Code A | —16,100 at $0.00 | filing |
| 28 Apr 2022filed 2 May 2022 | Invitaeoption or derivative | SEC FORM 4 Code A | —5,700 at $0.00 | filing |
| 28 Apr 2022filed 2 May 2022 | Invitae | SEC FORM 4 Code A | —32,100 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.